Kodiak Sciences Inc. Kodiak Sciences Inc.

Kodiak Sciences Inc.

KOD

शेयरों में रैंक #3070
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
शेयर मूल्य
$95.10
मार्केट कैप
$5.98B
बदलाव (1 दिन)
4.10%
बदलाव (1 वर्ष)
437.27%
देश
US
व्यापार Kodiak Sciences Inc. (KOD)

श्रेणी

Healthcare
Kodiak Sciences Inc. (KOD) के लिए डिविडेंड यील्ड इतिहास
Kodiak Sciences Inc. (स्टॉक सिंबल: KOD) की डिविडेंड यील्ड (TTM) 2023-12-31 को: 0.00%
पिछले 5 वर्षों की औसत डिविडेंड यील्ड: 0.00%
Kodiak Sciences Inc. (KOD) के लिए 2016 से 2026 तक की डिविडेंड यील्ड का इतिहास
प्रत्येक वर्ष के अंत में डिविडेंड यील्ड (TTM)
वर्ष डिविडेंड यील्ड परिवर्तन
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
समान कंपनियों या प्रतिस्पर्धियों के लिए डिविडेंड यील्ड (TTM)
कंपनी डिविडेंड यील्ड देश
0.00%
US
0.00%
US
2.17%
AU
0.00%
CH
0.00%
NL